Comprehensive Cancer Imaging Centre, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, UK.
Integr Biol (Camb). 2010 Oct;2(10):483-95. doi: 10.1039/c0ib00066c. Epub 2010 Aug 25.
Cancer is characterized by deregulation of cell proliferation and altered cell death apoptosis, which constitutes, in almost all instances, the minimal common platform upon which all neoplastic evolution occurs. The most implicit and clinically attractive anticancer strategies, therefore, consist of eliminating tumor cells by preventing their expansion and ultimately inducing cell death apoptosis. In this context, the non-invasive molecular assessment of tumor cell proliferation and apoptosis status using PET imaging constitutes a major strategy in preclinical studies to assess the efficacy of new anticancer therapeutics using small animal PET imaging, and in clinical settings for the monitoring of treatment responses in patients. For this purpose, a variety of PET tracers targeting specific molecular entities allowing the non-invasive measurement of biological processes, including cell proliferation and apoptosis, are under development for use in preclinical studies and clinical trials to non-invasively image in vivo the lifeline of tumors.
癌症的特征是细胞增殖失控和细胞死亡凋亡改变，这几乎构成了所有肿瘤发生的最小共同平台。因此，最隐性和最具临床吸引力的抗癌策略包括通过防止肿瘤细胞的扩张并最终诱导细胞死亡凋亡来消除肿瘤细胞。在这种情况下，使用正电子发射断层扫描（PET）成像对肿瘤细胞增殖和凋亡状态进行非侵入性分子评估，是在临床前研究中使用小动物 PET 成像评估新型抗癌疗法疗效的主要策略，也是在临床环境中监测患者治疗反应的主要策略。为此，正在开发各种针对特定分子实体的 PET 示踪剂，以允许对包括细胞增殖和凋亡在内的生物过程进行非侵入性测量，用于临床前研究和临床试验，以非侵入性地对肿瘤的生命线进行体内成像。
